ArticleNature2023
Interferon-ε is a tumour suppressor and restricts ovarian cancer.
Abstract read
In one paragraph
Article in Nature, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed
18.3field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 67 citations in OpenAlex.
- Multi-omics analysis reveals the attenuation of the interferon pathway as a driver of chemo-refractory ovarian cancer.Cell reports. Medicine · 2025Trial
- BRCA1 deficiency induces NFκB-dependent type-I interferon signaling in fallopian tube epithelial cells.Neoplasia (New York, N.Y.) · 2026Article
- Article
- Striking the right balance with type I interferon signalling in cancer.Nature reviews. Cancer · 2026Review
- Arginine dependency in omental metastasis of epithelial ovarian cancer reveals a therapeutic vulnerability.Cell death & disease · 2026Article
- The role of cytokines in ovarian cancer drug resistance.International journal of cancer · 2026Review
- Modeling ovarian cancer chemoresistance: establishment of murine ID8 sublines and elucidation of adaptive mechanisms.Frontiers in oncology · 2026Article
- Encapsulated Primary Human Ovarian Cancer Cells on Chips for Chemotherapy Drug Evaluation.Research (Washington, D.C.) · 2026Article
- EPI-SauriCas9-based mouse ovarian cancer models recapitulating pten deletion in patients.Communications biology · 2025Article
- Role of the tumor microenvironment in chemotherapy resistance in ovarian cancer and targeted therapy.Journal of ovarian research · 2025Review
- Interferon signaling pathways in health and disease.Molecular biomedicine · 2025Review
- Mapping the stage-specific plasma p53 interactome reveals colorectal cancer progression signatures and therapeutic vulnerabilities.The journal of liquid biopsy · 2025Article
- Interferon Epsilon Loss Is Elusive 9p21 Link to Immune-Cold Tumors, Resistant to Immune Checkpoint Therapy, and Endogenous CXCL9/10 Induction.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2025Review
- Interferons in health and disease.Cell · 2025Review
- Interferon-epsilon, an estrogen-induced type I interferon, is uniquely exploited by Neisseria gonorrhoeae via effects on sialic acid metabolism.Cell host & microbe · 2025Article
- Article
- Multimodal Spatial Profiling Reveals Immune Suppression and Microenvironment Remodeling in Fallopian Tube Precursors to High-Grade Serous Ovarian Carcinoma.Cancer discovery · 2025Article
- Direct cell interactions potentially regulate transcriptional programmes that control the responses of high grade serous ovarian cancer patients to therapy.Scientific reports · 2025Article
- A noncanonical role of SAT1 enables anchorage independence and peritoneal metastasis in ovarian cancer.Nature communications · 2025Article
- PJA2 Suppresses Colorectal Cancer Progression by Controlling HDAC2 Degradation and Stability.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
Corrections and comments
- Commented on by
Authors and funding
28 authors at 7 institutions in 3 countries.
Zoe R C Marks *Centre for Innate Immunity and Infectious Diseases, Hudson Institute of Medical Research, Clayton, Victoria, Australia.
Nicole K Campbell *Centre for Innate Immunity and Infectious Diseases, Hudson Institute of Medical Research, Clayton, Victoria, Australia.ORCID 0000-0002-9402-274X
Niamh E ManganCentre for Innate Immunity and Infectious Diseases, Hudson Institute of Medical Research, Clayton, Victoria, Australia.
Cassandra J VandenbergWalter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia.
Linden J GearingCentre for Innate Immunity and Infectious Diseases, Hudson Institute of Medical Research, Clayton, Victoria, Australia.ORCID 0000-0003-3508-3056
Antony Y MatthewsCentre for Innate Immunity and Infectious Diseases, Hudson Institute of Medical Research, Clayton, Victoria, Australia.ORCID 0000-0003-2342-2559
Jodee A GouldCentre for Innate Immunity and Infectious Diseases, Hudson Institute of Medical Research, Clayton, Victoria, Australia.
Michelle D TateCentre for Innate Immunity and Infectious Diseases, Hudson Institute of Medical Research, Clayton, Victoria, Australia.
Georgie Wray-McCannCentre for Innate Immunity and Infectious Diseases, Hudson Institute of Medical Research, Clayton, Victoria, Australia.
Le YingCentre for Innate Immunity and Infectious Diseases, Hudson Institute of Medical Research, Clayton, Victoria, Australia.
Sarah RosliCentre for Innate Immunity and Infectious Diseases, Hudson Institute of Medical Research, Clayton, Victoria, Australia.ORCID 0000-0001-7820-1484
Natasha BrockwellResearch Division, Peter McCallum Cancer Centre, Melbourne, Victoria, Australia.
Belinda S ParkerResearch Division, Peter McCallum Cancer Centre, Melbourne, Victoria, Australia.ORCID 0000-0002-8333-1926
San S LimCentre for Innate Immunity and Infectious Diseases, Hudson Institute of Medical Research, Clayton, Victoria, Australia.
Maree BilandzicDepartment of Molecular and Translational Science, Monash University, Clayton, Victoria, Australia.
Elizabeth L ChristieResearch Division, Peter McCallum Cancer Centre, Melbourne, Victoria, Australia.
Andrew N StephensDepartment of Molecular and Translational Science, Monash University, Clayton, Victoria, Australia.
Eveline de GeusCentre for Innate Immunity and Infectious Diseases, Hudson Institute of Medical Research, Clayton, Victoria, Australia.
Matthew J WakefieldWalter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia.ORCID 0000-0001-6624-4698
Gwo-Yaw HoWalter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia.
Orla McNallyResearch Division, Peter McCallum Cancer Centre, Melbourne, Victoria, Australia.
Australian Ovarian Cancer Study
Iain A McNeishOvarian Cancer Action Research Centre, Division of Cancer, Department of Surgery and Cancer, Imperial College London, London, UK.ORCID 0000-0002-9387-7586
David D L BowtellResearch Division, Peter McCallum Cancer Centre, Melbourne, Victoria, Australia.
Nicole A de WeerdCentre for Innate Immunity and Infectious Diseases, Hudson Institute of Medical Research, Clayton, Victoria, Australia.
Clare L ScottWalter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia.ORCID 0000-0002-3689-5956
Nollaig M BourkeCentre for Innate Immunity and Infectious Diseases, Hudson Institute of Medical Research, Clayton, Victoria, Australia.ORCID 0000-0003-4313-6859
Paul J HertzogCentre for Innate Immunity and Infectious Diseases, Hudson Institute of Medical Research, Clayton, Victoria, Australia. paul.hertzog@hudson.org.au.ORCID 0000-0002-1373-8472
Hudson Institute of Medical Research · AUPeter MacCallum Cancer Centre · AURoyal Women's Hospital · AUThe University of Melbourne · AUQIMR Berghofer Medical Research Institute · AUThe University of Sydney · AUTrinity College Dublin · IE
Funding
No grant is acknowledged in the PubMed record.
Abstract
High-grade serous ovarian cancers have low survival rates because of their late presentation with extensive peritoneal metastases and frequent chemoresistance
Indexed as
Interferon Type IOvarian NeoplasmsTumor Suppressor ProteinsAnimalsCell Line, TumorEpithelial CellsFallopian TubesFemaleGenes, BRCA1Genes, BRCA2Genes, p53HumansInterferonsKiller Cells, NaturalReceptor, Interferon alpha-betaT-LymphocytesIFNAR1 protein, humanIFNE protein, humanInterferonsInterferon Type IReceptor, Interferon alpha-betaTumor Suppressor Proteins
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.